Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia



Rating:

Share or cite this content

Citations should be made in the following way:
E. Lee (Seoul, Republic of Korea), T. Lee (Seoul, Republic of Korea), Y. Hong (Seoul, Republic of Korea), J. Ryoo (Seoul, Republic of Korea), J. Heo (Seoul, Republic of Korea), H. Kang (Seoul, Republic of Korea), S. Kwon (Seoul, Republic of Korea), Y. Kim (Seoul, Republic of Korea). Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study. 478

Member's Comments

No comment yet.

Related content which might interest you: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry Source: Eur Respir J, 56 (2) 1902279; 10.1183/13993003.02279-2019 Year: 2020 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients? Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function Source: Eur Respir J 2016; 48: 843-851 Year: 2016 Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Reply: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 57 (3) 2100283; 10.1183/13993003.00283-2021 Year: 2021 Comment on: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 57 (3) 2004645; 10.1183/13993003.04645-2020 Year: 2021 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 MUC5B genotype affects survival of patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016 Hyaluroman syntehase-2 over expression has impact in the evolution and on the prognosis of idiopathic pulmonary fibrosis patients Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Diaphragm dysfunction in combination with lung function decline is associated with higher mortality in idiopathic pulmonary fibrosis patients Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias Year: 2018 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema Source: Eur Respir J 2011; 37: 176-183 Year: 2011 The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 A comparison of the effects of lung function between low dose theophylline and oral β2-agonist in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 215s Year: 2006